Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: VistaGen Therapeutics Inc. VTGN

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing Requirements

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced its receipt of notice from The Nasdaq Stock Market on Jan. 5, 2021, that VistaGen has regained compliance … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Featured in Equity Research Report

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Commencement, Pricing of Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the commencement and pricing of an underwritten public offering. The offering consists of 63,000,000 shares of its common … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine

VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States

VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment Prevalence of depressive disorders in U.S. … Continue reading

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided … Continue reading

Posted in MissionIRNewsBreaks, VistaGen Therapeutics Inc. VTGN | Leave a comment